Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7188520 | 0.99 | ITGB1 (0.44) | NR5A1TP53TSHRPLA2G4BITGB1 | |
| SCHEMBL7180410 | 0.96 | ITGB1 (0.41) | NR5A1TP53TSHRPLA2G4BITGB1 | |
| SCHEMBL7177602 | 0.92 | L3MBTL1 (0.41) | ITGB1ITGA4THRBLTA4H | |
| SCHEMBL7179956 | 0.89 | ITGB1 (0.54) | NR5A1TP53TSHRPLA2G4BITGB1 | |
| SCHEMBL7179647 | 0.88 | ITGB1 (0.55) | NR5A1TP53TSHRPLA2G4BITGB1 | |
| SCHEMBL7175718 | 0.87 | EPHX2 (0.45) | LTA4H | |
| SCHEMBL7188725 | 0.86 | THRB (0.44) | TP53TSHRPLA2G4BITGB1ITGA4 | |
| SCHEMBL7180396 | 0.86 | THRA (0.39) | THRATHRB | |
| SCHEMBL7177180 | 0.86 | CACNA1H (0.39) | — | |
| SCHEMBL7182620 | 0.85 | NR5A1 (0.50) | NR5A1TP53TSHRPLA2G4BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | NR5A1 49/4885TP53 3575/4885TSHR 984/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | NR5A1 133/4885TP53 3524/4885TSHR 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.